Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer.

Kou T, Kanai M, Ikezawa K, Ajiki T, Tsukamoto T, Toyokawa H, Yazumi S, Terajima H, Furuyama H, Nagano H, Ikai I, Kuroda N, Awane M, Ochiai T, Takemura S, Miyamoto A, Kume M, Ogawa M, Takeda Y, Taira K, Ioka T.

J Gastroenterol Hepatol. 2014 Feb;29(2):403-8. doi: 10.1111/jgh.12338.

PMID:
23869919
2.

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.

Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.

BMC Cancer. 2008 Dec 18;8:374. doi: 10.1186/1471-2407-8-374.

3.

Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.

Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K.

Cancer Chemother Pharmacol. 2011 Apr;67(4):847-53. doi: 10.1007/s00280-010-1360-7. Epub 2010 Jun 20.

PMID:
20563811
4.

Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.

Yukisawa S, Ishii H, Matsuyama M, Kuraoka K, Takano K, Kamei A, Ozaka M.

Jpn J Clin Oncol. 2011 Jan;41(1):76-80. doi: 10.1093/jjco/hyq160. Epub 2010 Oct 5.

5.

A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.

Kameda R, Ando T, Kobayashi S, Ueno M, Ohkawa S.

Jpn J Clin Oncol. 2013 Jun;43(6):636-40. doi: 10.1093/jjco/hyt059. Epub 2013 Apr 25.

6.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8. Epub 2006 Dec 2.

PMID:
17143602
7.

Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.

Lamarca A, Benafif S, Ross P, Bridgewater J, Valle JW.

Eur J Cancer. 2015 Sep;51(13):1694-703. doi: 10.1016/j.ejca.2015.05.018. Epub 2015 Jun 8.

PMID:
26066735
8.
9.

A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.

Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.

Cancer Chemother Pharmacol. 2009 Dec;65(1):113-20. doi: 10.1007/s00280-009-1011-z. Epub 2009 Apr 29.

PMID:
19404641
10.

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY.

Lancet Oncol. 2012 Feb;13(2):181-8. doi: 10.1016/S1470-2045(11)70301-1. Epub 2011 Dec 20. Erratum in: Lancet Oncol. 2012 Feb;13(2):e49. Chang, Joung Soon [corrected to Jang, Joung Soon].

11.

Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.

Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research.

J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.

12.

A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.

Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S.

Jpn J Clin Oncol. 2012 Sep;42(9):800-6. doi: 10.1093/jjco/hys102. Epub 2012 Jul 23.

13.

Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.

Huggett MT, Passant H, Hurt C, Pereira SP, Bridgewater J, Mukherjee S.

Tumori. 2014 Mar-Apr;100(2):219-24. doi: 10.1700/1491.16421.

PMID:
24852869
14.

Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.

Woo SM, Lee WJ, Kim JH, Kim DH, Han SS, Park SJ, Kim TH, Lee JH, Koh YH, Hong EK.

Chemotherapy. 2013;59(3):232-8. doi: 10.1159/000354539. Epub 2013 Dec 13.

PMID:
24356333
15.
16.

A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.

Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T.

Jpn J Clin Oncol. 2007 Nov;37(11):843-51. Epub 2007 Oct 17.

17.

Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.

Mir O, Coriat R, Dhooge M, Perkins G, Boudou-Rouquette P, Brezault C, Ropert S, Durand JP, Chaussade S, Goldwasser F.

Anticancer Drugs. 2012 Aug;23(7):739-44. doi: 10.1097/CAD.0b013e3283556b9b.

PMID:
22700002
18.

Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.

Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Yagioka H, Matsubara S, Hanada K, Maguchi H, Kamada H, Hasebe O, Mukai T, Okabe Y, Maetani I, Koike K.

World J Gastroenterol. 2014 Dec 28;20(48):18452-7. doi: 10.3748/wjg.v20.i48.18452.

19.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K.

Cancer. 2006 Mar 15;106(6):1339-46.

20.

Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.

Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N.

Jpn J Clin Oncol. 2006 Sep;36(9):552-6. Epub 2006 Aug 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk